{"nctId":"NCT02094586","briefTitle":"A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults","startDateStruct":{"date":"2014-05"},"conditions":["Cholera"],"count":3146,"armGroups":[{"label":"PXVX0200 Lot A","type":"EXPERIMENTAL","interventionNames":["Biological: PXVX0200 Lot A"]},{"label":"PXVX0200 Lot B","type":"EXPERIMENTAL","interventionNames":["Biological: PXVX0200 Lot B"]},{"label":"PXVX0200 Lot C","type":"EXPERIMENTAL","interventionNames":["Biological: PXVX0200 Lot C"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"PXVX0200 Lot A","otherNames":[]},{"name":"PXVX0200 Lot B","otherNames":[]},{"name":"PXVX0200 Lot C","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy men or women,\n* age 18 to 45 years inclusive;\n* normal medical history and physical examination\n* Women must have a negative pregnancy test.\n\nExclusion Criteria:\n\n* travel to a cholera endemic area in the previous 5 years;\n* abnormal stool pattern or regular use of laxatives;\n* Currently active unstable or undiagnosed medical conditions\n* current or recent antibiotic use;\n* pregnancy or nursing;\n* Previously received a licensed or investigational cholera vaccine\n* History of cholera or enterotoxigenic E. coli infection\n* History of Guillain-Barré Syndrome\n* Received or plans to receive any other licensed vaccines, except for seasonal influenza\n* Recipient of bone marrow or solid organ transplant\n* Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years\n* Use of systemic chemotherapy in the previous 5 years prior to the study\n* any immunosuppressive medical condition","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B","description":"The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5. Placebo GMT values were not included in the primary analysis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9220","spread":null},{"groupId":"OG001","value":"10034","spread":null}]}]}]},{"type":"SECONDARY","title":"SVA Seroconversion at Day 11","description":"Percentage of subjects who demonstrated a ≥4-fold rise over baseline in serum vibriocidal antibody (SVA) at Day 11","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"SVA and Anti-CT IgG GMT at Day 1, 11, 29, 91 and 181","description":"GMTs of vibriocidal antibody and anti-CT IgG concentrations at Days 1, 11, 29, 91, and 181.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9922","spread":null},{"groupId":"OG001","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6170","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"560","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"445","spread":null},{"groupId":"OG001","value":"951","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1780","spread":null},{"groupId":"OG001","value":"800","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2007","spread":null},{"groupId":"OG001","value":"848","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1276","spread":null},{"groupId":"OG001","value":"599","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1116","spread":null},{"groupId":"OG001","value":"528","spread":null}]}]}]},{"type":"SECONDARY","title":"SVA and Anti-CT IgG Seroconversion at Day 1, 11, 29, 91 & 181","description":"Proportion of subjects who demonstrated a ≥4-fold rise over baseline in vibriocidal antibody and anti-CT IgG concentration from baseline at Days 1, 11, 29, 91, and 181. Day 1 not reported as seroconversion on Day 1 not applicable.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, fever \\& vomiting were collected from Day 1 - 8.\n\nIncidence and severity of unsolicited adverse events were collected till Day 29.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.99","spread":null},{"groupId":"OG001","value":"50.44","spread":null},{"groupId":"OG002","value":"52.28","spread":null},{"groupId":"OG003","value":"51.90","spread":null},{"groupId":"OG004","value":"43.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":null},{"groupId":"OG001","value":"3.96","spread":null},{"groupId":"OG002","value":"3.36","spread":null},{"groupId":"OG003","value":"3.88","spread":null},{"groupId":"OG004","value":"1.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":null},{"groupId":"OG001","value":"0.77","spread":null},{"groupId":"OG002","value":"0.33","spread":null},{"groupId":"OG003","value":"0.62","spread":null},{"groupId":"OG004","value":"1.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.03","spread":null},{"groupId":"OG001","value":"18.94","spread":null},{"groupId":"OG002","value":"18.00","spread":null},{"groupId":"OG003","value":"18.32","spread":null},{"groupId":"OG004","value":"15.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.09","spread":null},{"groupId":"OG001","value":"26.43","spread":null},{"groupId":"OG002","value":"30.26","spread":null},{"groupId":"OG003","value":"28.93","spread":null},{"groupId":"OG004","value":"23.62","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots B and C","description":"The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10034","spread":null},{"groupId":"OG001","value":"9827","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and C","description":"The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9220","spread":null},{"groupId":"OG001","value":"9827","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":926},"commonTop":["Headache","Fatigue","Upper Respiratory Tract Infection","Back Pain","Flatulence"]}}}